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Abstract
Background: An implant coating with poly(D, L-lactide) (PDLLA) releasing incorporated Zoledronic acid (ZOL) has
already proven to positively effect osteoblasts, to inhibit osteoclasts and to accelerate fracture healing. Aim of this
study was to investigate the release kinetics of the chosen coating and the effect of different concentrations of
ZOL locally released from this coating on the osseointegration of implants.
Methods: For release kinetics the release of C14-labled ZOL out of the coating was monitored over a period of six
weeks in vitro. For testing the osseointegration, titanium Kirschner wires were implanted into the medullary canal
of right femurs of 100 Sprague Dawley rats. The animals were divided into five groups receiving implants either
uncoated or coated with PDLLA, PDLLA/ZOL low (1.2% w/w) or PDLLA/ZOL high (2% w/w). Additionally, a group
with uncoated implants received ZOL intravenously (i.v.). After 56 days animals were sacrificed, femurs dissected
and either strength of fixation or histological bone/implant contacts and newly formed bone around the implants
were determined.
Results: Release kinetics revealed an initial peak in the release of C14-ZOL with a slight further progression over
the following weeks. There was no significant enhancement of osseointegration for both groups who received
ZOL-coated implants or ZOL i.v. compared to the controls in biomechanical or histological analyses, except for a
significant raise in strength of fixation of ZOL i.v. versus PDLLA.
Conclusions: Even though the investigated local ZOL application did not enhance the osseointegration of the
implant, the findings might support its application in fracture treatment, since fracture stabilization devices are
often explanted after consolidation.
Background
Implants commonly used in orthopedic surgery serve on
the one hand as fixation devices after fractures, granting
stabilization until fracture healing. On the other hand
implants are used for joint replacement and a persistent
osseointegration is desired. However, failure of osseoin-
tegration in joint replacement is a frequent complica-
tion. To address this issue, research has recently been
focused on the supplementary use of drugs that are
known to influence bone turnover. In particular, the
class of Bisphosphonates (BPs) has been evaluated for
improvement of both, fracture healing and osseointegra-
tion in animal models [1-8] and clinical studies [9,10].
BPs such as Zoledronic acid (ZOL) are in clinical use
for prevention and treatment of skeletal diseases asso-
ciated with increased bone resorption like malignant
tumors [11,12] or osteoporosis [8,9]. As BPs have a
strong affinity to Calcium, they almost exclusively con-
centrate in bone mineral, mainly in regions of bone
resorption or formation. Incorporated by osteoclasts
during bone resorption, Nitrogen-containing BPs such
as ZOL block the farnesyl pyrophosphate synthase, a
crucial enzyme in the mevalonate pathway, which inter-
feres with the prenylation of proteins causing functional
impairment of osteoclasts and thus a decrease in bone
resorption [13].
The influence of BPs on bone healing and the osseoin-
tegration of implants have been widely investigated.
During bone repair, BPs have been shown to have an
anti-catabolic, almost net anabolic effect [14,15]. In
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most studies, this resulted in the enhancement of frac-
ture consolidation [16,17]. Concerning osseointegration,
studies focused on the effect of systemically or locally
applied BPs on implant fixation [10,18]. Locally, BPs
were either applied directly to the implant site or linked
to the implant with a coating substance as drug carrier
[1,19]. Different coatings were tested using especially
calcium phosphates like hydroxyapatite [20-22] or cross-
linked fibrinogen layer [23-25]. In most cases, applica-
tion of BPs showed beneficial biomechanical and histo-
logical effects on implant osseointegration [1,23,25-27].
However, in some studies, BPs did not improve implant
fixation or even worsened it [28-30].
Previous in vitro studies investigated the effect of locally
released ZOL from a poly(D, L-lactide) (PDLLA) implant
coating on human osteoblasts and osteoclasts. A dose
dependent promoting effect on osteoblasts [31] and a
decrease in osteoclast formation and osteoclastic resorption
activity [32] could be shown. In a coculture of human osteo-
blasts and osteoclasts, beneficial effects on osteoblast differ-
entiation and protein synthesis and a decrease of osteoclast
formation with no significant decrease in osteoclastic
resorption activity has also been shown [33]. Moreover, in a
rat fracture model, local application of ZOL delivered from
an intramedullary implant showed a significant increase in
biomechanical strength of the fracture side [17].
Aims of the study were first to investigate the release
kinetics of the chosen PDLLA/ZOL coating. Second, to
analyze the effect of the coating on osseointegration of
implants using an established non-weight-bearing rat
implant model [34]. Third, to detect possible differences




To detect the release profile of ZOL from PDLLA, an in
vitro elution experiment was performed. Titanium K-
wires were dip coated in a solution with Carbon 14(C14)-
labeled ZOL (Novartis Pharma AG, Basel, Switzerland)
dissolved in PDLLA/ethyl acetate resulting in an esti-
mated concentration of 50 μg per sample. Ten Titanium
K-wires with PDLLA/C14-ZOL coating were sterile incu-
bated at 37°C (each in 5.2 mL 0.9% NaCl). At time points
0 min, 10 min, 1 h, 6 h, 12 h, 24 h, 48 h, 4 d, 7 d, 14 d, 28
d, and 42 d 100 μL were drawn from each solution. The
concentrations of C14-ZOL were detected indirectly via
radioactivity count as automatically quench-corrected
Counts Per Minute (CPM) by a Liquid Scintillation
Counter (Wallac Oy, Turku, Finland).
Coating of the implants and groups
Coating of the implants was performed as described pre-
viously [35]. After dissolving 100 mg PDLLA in 1.5 ml
ethyl acetate at room temperature, the solution was ster-
ile filtered. ZOL was dissolved in ethyl acetate/PDLLA
solution to obtain a concentration of 1.2% w/w or 2%
w/w. Sterile Kirschner wires (1.4-mm diameter,
Synthes®, Paoli, USA) were used as implants for the
experiments. They were dipped two times into the coat-
ing solution and dried under laminar air flow condi-
tions. For systemic application ZOL was dissolved in
NaCl to obtain a concentration of 0.1 mg/ml. The study
contained five groups:
- - Group I (Control)-uncoated K-wire
- - Group II (PDLLA)-PDLLA
- - Group III (ZOL low)-PDLLA + ZOL low dose (20
μg, 1.2% w/w)
- - Group IV (ZOL high)-PDLLA + ZOL high dose
(50 μg, 2% w/w)
- - Group V (ZOL i.v.)-uncoated + ZOL i.v. 0.1 mg/kg
Zoledronic acid as a pure substance was kindly pro-
vided by Novartis Pharma AG (Basel, Switzerland).
Animals and experimental design
Animals used for experiment were 100 five-month-old
female Sprague Dawley rats (Harlan-Winkelmann, Ger-
many) with a mean body weight of 267 g +/- 25 g (SD).
They were kept in groups of five rats each. For anesthesia
isoflurane gas (Forene®) and an intraperitoneal injection
with a mixture of Ketaminhydrochlorid (100 mg/ml per
80 mg/kg body weight) and Xylazin 2% (12 mg/kg body
weight) were used. The right hind leg was shaved for
operation. A 3 mm longitudinal incision was made to
split the skin and the patellar ligament. Using a 1.2 mm
hand drill, the intracondylar notch of the right femur was
reamed. Thereafter, insertion of the implant into the
medullary cavity to the proximal end was performed in a
retrograde manner. Radiographs were taken to verify the
correct position of the implant using the trochanter
major as control point. At the end of operation the
extending part of the implant was cut off and skin
wounds were sutured. For systemic application of ZOL
either the cephalic vein or the left greater saphenous vein
were used. Immediately after implant insertion, ZOL dis-
solved in 1 ml NaCl was injected into the vein.
After the operation and on the first postoperative day
all animals received subcutaneous injections of bupre-
norphine (Temgesic®, 0.05 mg/kg) for analgesia. Using a
precision scale, body weight was determined and body
temperature was measured rectally at days 0 (OP) and
56. Wound healing and signs of a local or systemic
infection were evaluated regularly. 56 days after opera-
tion, animals were sacrificed for biomechanical and his-
tological analysis. The national guidelines for the care
and use of laboratory animals were observed and the
study was approved by the Animal Experimental Ethics
Committee of Berlin (approval number G0174/07).
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Radiographic evaluation
Radiographs were taken in lateral and posterior-anterior
view at day 0 (operation) and at day 56 (sacrifice) with
the use of digital X-ray cassettes (Fuji Photo Film Co.,
Fuji, Japan) and a Mobilett Plus X-ray unit (Siemens
AG, Munich, Germany). The X-rays were evaluated by
two observers.
Biomechanical testing
All rats were sacrificed after 56 days and 10 animals of
each group were taken for biomechanical analysis. The
right femurs were dissected and soft tissue was removed.
Afterwards, they were carefully prepared at the proximal
and distal end to expose 3 mm of the implant on each
side of the bone. The distal end was embedded with
bone cement (Heraeus-Kulzer GmbH, Wehrheim, Ger-
many) into a previously described push-out device [34],
which was placed into a material testing machine
(Zwick 1455, Ulm, Germany). During the test, the
machine applied a constant linear propulsion (v = 2
mm/min) to the implant and the applied force was
recorded. For measuring the bone-implant attachment
strength, the peak force needed to loosen the implant
was used. To minimize differences in the push-out force
due to a different length of the bone or implant, maxi-
mum force was set in ratio to the total bone area in
contact with the implanted K-wire [26,34]:
Strength of fixation σu = Fmax/πDH[σu : strength of fixation (Mpa), Fmax : initial push - out force
(N),D : implant diameter(mm),H : Bone length (mm)].
Histomorphometry
For histological assessment the right femur of 10 ani-
mals of each group was harvested and cleared of soft tis-
sue. The bones were fixed in 10% normal buffered
formaldehyde for 5 days, dehydrated by ascending con-
centrations of ethanol and finally embedded in methyl-
methacrylate (Technovit 7200, Heraeus-Kulzer GmbH,
Wehrheim, Germany). A grinding machine (Exakt, Nor-
derstedt, Germany) was used to grind the embedded
specimens until the implant was visible in full length
with maximum diameter. After gluing the ground sides
to microscope slides, a diamond band saw (Exakt, Nor-
derstedt, Germany) was used to slice 300 μm sections
which were ground down to 80 μm. The staining for
histological analyses of the sections was performed with
Safranin-O and von-Kossa. The specimens were scanned
with a microscope (Axioskop 40, Carl Zeiss, Göttingen
Germany). Direct bone/implant contact area was deter-
mined with analyzing software (AxioVision Rel. 4.7, Carl
Zeiss AG, Jena, Germany). The region of interest (ROI)
was defined by drawing a line of exact the same length
(13.7 mm) in each digitalized picture, starting from the
nutrient foramen (Figure 1a). Afterwards, bone/implant
contact areas of both cortices were measured along the
distance of the drawn line and set into per cent ratio.
Furthermore, trabecular mass was measured within the
ROI in an 0.3 mm range on both sides of the implant
and set in per cent to the entire area of this spatium to
determine bone area/total area ratio (Figure 1b).
Statistics
Statistical differences between all groups were analyzed
with the Kruskal-Wallis test. If significant differences
were shown, Mann-Whitney U test was used for com-
parison between two single groups. Data were controlled
with Bonferroni-Holm correction for multiple compari-
sons. Statistical differences were defined at a 95% confi-




The release of the incorporated C14-ZOL from the
PDLLA coating showed a strong increase in detectable
Counts Per Minute (CPM) within the first hours. In the
following days and weeks, only a slight further progres-
sion of CPM took place, indicating that approximately
90% of C14-ZOL had been released in an initial peak
within the first 24 hours (Figure 2).
Body parameter evaluation and x-ray
No significant differences were detected in body tem-
perature and raise of average body weight between the
groups over the experimental period. None of the ani-
mals showed any clinical signs of infection throughout
the experimental period.
Immediate postoperative X-rays revealed a correct
insertion of each K-wire in all femurs. Evaluation cri-
teria were here the placement of each implant inside the
medullar canal with its tip positioned at the level of the
lesser trochanter. The X-ray control after 56 days (Fig-
ure 3) showed no signs of dislocation of the implants or
zones of osteolysis in all animals. Here, X-rays were ana-
lyzed in comparison to the postoperative records to
evaluate if the medullar canal had been widened and if
the position of the implants had varied, determined by
the location of the K-wire tip and two points of contact
with the cortical bone. Radiologically, there was no dif-
ference in implant/bone fitting between all groups.
Biomechanical evaluation
After determination of the strength of fixation by corre-
lating the initial push-out force of each implant with the
length of the surrounding bone, all groups were com-
pared with each other. The results of the PDLLA group
were slightly lower than those of the group with
uncoated pins. No significant difference in strength of
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Figure 1 (a) Histological sections of rat femurs (Region of interest: 13.7 mm from nutrient foramen; cutting zone of the bone) were
analyzed (b) for bone/implant contacts and bone area (in a 0.3 mm spatium from implant).
Figure 2 In vitro elution kinetics of Carbon 14-labeled ZOL from a PDLLA coating with an initial burst release of ZOL within the first
hours.
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fixation was found comparing the ZOL low and ZOL
high groups with the controls. The ZOL i.v. group
showed no significant difference to the group with
uncoated and ZOL-coated pins, whereas its results
were significantly higher than those of the PDLLA
group (Figure 4).
Histomorphological and histomorphometric evaluation
Newly formed bone was visible in the femoral cavities of
all animals, also in direct contact to the implants (Figure
5a-e). Regarding the amount of contact area of the
newly formed intramedullar bone and the implant sur-
face, there was no significant difference between all
groups (Figure 6a). Also no significant changes in bone
area/total area ratio were assessed between the groups
(Figure 6b).
Discussion
The purpose of this study was to investigate the release
kinetics of Zoledronic acid (ZOL) incorporated in a poly
(D, L-lactide) coating (PDLLA) and its effect on the
osseointegration of implants, compared to a systemic
ZOL application.
Release kinetics of ZOL out of the coating showed an
initial peak of approximately 90% in release of C14-
labled ZOL from PDLLA coated K-wires within the first
24 hours. The biomechanical and histological analyses
revealed a significant higher strength of fixation in the
group with systemic ZOL compared to PDLLA.
However, no enhancement of osseointegration in groups
treated with ZOL-coated implants in comparison to the
controls could be shown.
These results are in contrast to other studies, showing
an enhancement of osseo-integration or reduced implant
migration after systemic [12,18,36] or local
[1-3,8,19,27,28,30] application of Bisphosphonates (BPs).
Especially the BP ZOL, as used in this study, has been
shown to be among the most potent of its class [37].
However, existing studies vary in different aspects, such
as additional use of bone compaction [2,3], the used BPs
[7,27,28], the experimental model [14,20,30,38], animal
species [2,7,30] implants [2,14,20,38] and application
methods [7,38-40]. Among implant coatings, fibrinogen
[4,5,38] and especially hydroxyapatite (HA) [20,27,30]
have recently been used successfully to improve implant
fixation by local application of BPs. Studies using ZOL
locally were able to show an enhancement of peri-pros-
thetic bone quality and osseous integration by ZOL-
coated implants with a similar animal model [20] or a
significant enhancement of bone apposition and mean
amount of femoral canal filling even after one year com-
pared to controls [21]. Also a dose depending improve-
ment of histological and biomechanical results by ZOL-
application has been proved [14].
But there are also some studies where local BPs did
not improve the bone-implant integration or even
impaired it. After showing a benefit of local Alendronate
in the fixation of porous-HA-coated implants [2]
Figure 3 X-rays (posterior-anterior (a) and lateral (b)) the operated leg of an animal of the PDLLA-treated group at time of sacrifice.
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Jakobsen et al. detected a decrease in implant fixation
when using soaked morselized allograft with the same
dose and BP [29]. This effect, also shown in other stu-
dies with Pamidronate [28], could be due to the combi-
nation of densely compacted bone and BP [7]. But even
in other study designs locally applied BPs did not always
lead to significantly increased bone/implant contacts of
BP-coated implants [22] nor did the additional applica-
tion of BP enhance the biomechanical properties of
coated implants [23].
Regarding systemic delivery, BPs have been shown to
increase peri-implant bone density and implant-bone
contact ratio in animal [39,40] and clinical [9] studies.
Even though the same i.v. ZOL concentration (0.1 mg/
kg) was used as by Yu et al. [39], no improvement in
osseointegration was detected compared to the groups
with PDLLA/ZOL or uncoated implants, except for a
significant biomechanical enhancement in comparison
to the PDLLA group. A possible reason could be the
chosen time point of the application, being one week
after surgery for Yu et al. vs. immediately during surgery
in the presented study. This might have led to a stron-
ger impairment of bone catabolism.
There are different explanations for the positive effects
of BP in osseointegration. A reduction of implant migra-
tion by BPs, seen by Hilding and Aspenberg [19] was
probably due to the inhibition of the resorption of peri-
prosthetic necrotic bone [18].
Also bone formation around screws coated with fibri-
nogen, Pamidronate and Ibandronate was supposed to
be based on reduced bone loss due to BP with the
retained bone serving as scaffold for new bone cells
[38]. Thus the enhancement of periprosthetic stabiliza-
tion by BP appears to depend on the contact to sur-
rounding bone and maybe even a press fit position
[28,29]. Especially in a press fit situation the bone next
to the implant may be necrotic and prone to resorption
by osteoclasts. This resorption could be inhibited by BP,
leading to an enhanced implant fixation.
In the present study, however, the implant fixation
was not press fit in the medullary canal but in the cor-
tex of the insertion point. Therefore neither local nor
systemic inhibition of osteoclasts by ZOL might have
supported additional implant ingrowth.
Since the time point of BP application seems to be
decisive for its local effect on bone cells [39], data about
release kinetics is important for a better prediction
concerning the effect of the locally released BPs on the
osseointegration of implants. Few other studies dealing
with local release of BPs showed data for the individual
specific elution kinetics [4,37]. Regarding the used
coating, the present work is the first describing the
release kinetics of ZOL out of the PDLLA coating
[15,18-20].
However, even though the detected release kinetics
with an initial peak confirms previous findings for the
Figure 4 Push-out strength of fixation (MPa). There were no significant differences between ZOL low/high and the other groups. However,
the results of the ZOL i.v. group were significantly higher than those of the PDLLA group (* p = 0.002).
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Figure 5 a-Histological section of the femoral bone of an animal of the group without coating. b - Histological sections of the femoral
bone of an animal of the PDLLA-treated group. c - Histological sections of the femoral bone of an animal of the group with PDLLA/ZOL low
coated implants. d - Histological sections of the femoral bone of an animal of the group with ZOL high coated implants. e - Histological
sections of the femoral bone of an animal of the group which received ZOL intravenously.
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PDLLA coating [24] and though comparable kinetics
between a phosphate buffered saline solution and cell
culture medium have been shown [15], the here
obtained releasing curve of ZOL cannot reflect the true
release dynamics of intramedullary implants. Future stu-
dies will also have to investigate if the effect of the sub-
stance on bone cells could be improved by modification
of the coating and variation of the release resulting in a
slow sustained or delayed release [25]. In this context it
could be tried to use C14-labled ZOL with autoradio-
graphic analysis for local in vivo detection of released
ZOL [16] as systemic detection would not be promising
due to the high affinity of BPs to bones [13].
There are some limitations of this study. Among those
should be seen the single time point (56 days), as no
possible effect over time could be detected, even though
other experiments have shown that osseous integration
of implants was completed after six weeks [36]. Further
limiting was the fact that the chosen implant model was
not weight bearing and thereby effects of direct load
transfer were not addressed.
Retrospectively, the use of a micro-CT with its possibility
of a 3-D detection of newly formed bone or bone/implant
contacts should be seen as best method for this purpose and
would have avoided the danger of harming fragile structures
like trabeculae by histological preparation. Another short-
coming was the lack of direct determination of the bioactiv-
ity of C14-ZOL after coating and release from PDLLA.
However, previously published data has shown bioactivity of
PDLLA-released ZOL on human bone cells [31-33].
Conclusion
The time point of application as well as the way of implant
fixation (press fit) seem to be decisive for the effect of BP
in osseointegration. The presented model shows that a
PDLLA/ZOL coating does not lead to an enhancement of
osseointegration of non-press fit inserted implants. Further
studies will be necessary to clarify if the mechanism of
action of ZOL will lead to an improved osseointegration
in a press fit implant fixation model and if a coating with a
delayed release of the substance would lead to different
findings in osseointegration.
However, in fracture fixation where strong bone/
implant integration of intramedullary implants is an
undesirable effect, local application of ZOL to stimulate
fracture healing, as it has been described before [17],
may still be an option. Since fracture stabilization
devices are often explanted after consolidation, an
enhanced osseointegration would pose an undesirable
co-effect. Thus, the current findings are reassuring for
further investigations of this coating in the context of
fracture treatment with intramedullary implants.
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